Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887911 | 0.81 | MAPT (0.70) | POLBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL12661700 | 0.80 | ERCC5 (0.48) | POLBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1888538 | 0.80 | ERCC5 (0.48) | POLBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1894569 | 0.77 | MAPT (0.61) | POLBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1888108 | 0.77 | POLB (0.54) | POLBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1885612 | 0.76 | KDM4E (0.47) | POLBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1885613 | 0.76 | KDM4E (0.47) | POLBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1893162 | 0.75 | POLB (0.52) | POLBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1888266 | 0.74 | POLB (0.68) | POLBMAPTTP53 | |
| SCHEMBL1883471 | 0.74 | MAPT (0.55) | POLBMAPTERCC5FEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | claimed |
| WO-2006014647-A2 | CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF | ATHERSYS, INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2006014647-A2 | CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF | ATHERSYS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | FEN1, UNG, POLH | POLB 31/4885KDM4E 1575/4885ALDH1A1 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.